论文部分内容阅读
目的探讨沐舒坦治疗新生儿肺炎的最佳给药途径。方法将120例患者随机分成静脉滴注、雾化吸入与静脉滴注加雾化吸入三组,比较三组患者的疗效、住院天数、临床症状缓解时间。结果静脉滴注加雾化吸入组的有效率87.5%,静脉滴注组有效率80%,单纯雾化吸入组有效率为55%。静脉滴注加雾化吸入组临床症状缓解时间与雾化吸入组间差异显著(p<0.01),与静脉滴注组间差异无统计学意义(p>0.05)。静脉滴注组与雾化吸入组间临床症状缓解时间差异无统计学意义(p>0.05)。结论对于一般的患者,只需要静脉给予沐舒坦就能很好地缩短临床症状缓解时间,只有对肺部罗音明显,痰量较多,明显影响到通气功能者,才需要联合静脉滴注与雾化吸入沐舒坦。
Objective To investigate the optimal route of administration of mucosolvan in the treatment of neonatal pneumonia. Methods 120 patients were randomly divided into three groups: intravenous drip, nebulized inhalation and intravenous drip plus nebulization. The curative effect, hospitalization days and clinical symptom relief time of the three groups were compared. Results The results showed that the effective rate of intravenous drip plus atomized inhalation group was 87.5%, the effective rate of intravenous drip group was 80%, and the effective rate of pure atomized inhalation group was 55%. There was a significant difference between the two groups (p <0.01). There was no significant difference between the intravenous drip group and the intravenous drip group (p> 0.05). There was no significant difference in the clinical symptoms between intravenous drip group and nebulized group (p> 0.05). Conclusion For general patients, just intravenous administration of ambroxol can shorten the clinical symptoms of remission time, only obvious pulmonary rales, sputum volume, significantly affect the ventilation function, only need intravenous infusion and Inhaled inhaled mucosolvan.